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Summary
BACKGROUND 
 Suboptimal growth and certain metabolic disorders are commonly presented by children 
with Sickle Cell Disease (SCD).  SCD is an autosomal recessive genetic condition common in 
regions with intense malaria prevalence. The cycles of de-oxygenation and oxygenation of red 
blood cells producing repeated sickling and unsickling, leading to red cell damage is a concern.
 There was need to establish the cause of common triggers for Vaso-Occlusive crises which 
include dehydration, infections, extreme temperature and emotional stress. Recurrent painful 
episodes, several physical and biochemical disorders including suboptimal growth, low immunity, 
anemia and a variety of serious organ system complications that cause life-long disabilities and/or 
early death in HbSS patients was a challenge. The highest frequencies (3 to 4% of populations) of 
Homozygous Sickle Cell disease occur in Sub-Saharan Africa. 
METHODOLOGY
 Twenty eight children aged 4-10 years with Hemoglobin-SS (HbSS) and Vaso-Occlusive 
crisis attending Children Emergency Clinic at Ladoke Akintola University of Technology Teaching 
Hospital and another 30 healthy sex and age matched children with HbAA (controls) participated 
in this study. Plasma levels of Growth Hormone(GH), cortisol, prolactin, Total Thyroxin(TT4), 
Total Triiodotyronine(TT3), Thyroid Stimulating Hormone(TSH) and insulin were determined in 
all respondents using enzyme linked immunosorbent assay methods. 
RESULTS 
 The weight, height and BMI decreased significantly (p<0.05) in HbSS children compared 
with the controls. Plasma levels of GH, cortisol, TT3 and TT4 increased significantly (p<0.05) 
in HbSS-children compared with controls. Plasma levels of prolactin, TSH and insulin did not 
show significant (p>0.05) changes in the HbSS children compared with the controls. There was 
a significant (r=0.46, p=0.04) positive correlation between cortisol and GH in the children with 
HbSS. A negative correlation (r=-0.45, p=0.045) existed between TT4 and weight of HbSS-
children.
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Introduction
 Sickle cell disease (SCD) is an autosomal 
recessive genetic condition common in regions of the 
world with intense malaria prevalence. The highest 
frequencies (3 to 4% of populations) of Homozygous 
Sickle cell disease occur in mainly in Sub-Saharan 
Africa [1]. 
	 The	replacement	of	glutamic	acid	of	the	β-chain	
by valine at the 6th position accounts for the mutation 
of the adult haemoglobin to Sickle Hemoglobin (HbS). 
The HbS had the ability to polymerize by hydrophobic 
interaction at low oxygen concentration [2] leading 
to Poikilocytosis and Vaso-Occlusion. That was the 
main specific manifestation of SCD, differentiating it 
from other hemolytic anemias. Common triggers for 
Vaso-Occlusive crises include dehydration, infections, 
extreme temperature, and emotional stress. 
 However, often no identifiable cause was found 
and pain usually occurred without warning [3, 4]. Cycles 
of de-oxygenation and oxygenation of red blood cells 
produced repeated sickling and unsickling, leading to 
red cell damage [5]. Previous studies showed that at birth, 
SCD infants are normal in size, but by 2–5 years of age, 
significant deficits [6, 7] leading to recurrent painful 
episodes, several physical and biochemical disorders 
including suboptimal growth, low immunity, anemia 
and a variety of serious organ system complications 
that could cause life-long disabilities and/or early death 
were apparent [7, 8, 9, 10]. Increased energy and micro-
nutrient requirements with endocrine abnormalities 
have been reported in HbSS patients [11]. 
 Growth hormone abnormalities [6, 7, 12], and 
certain endocrine dysfunctions have been associated 
with suboptimal growth and development in HbSS 
children [13, 14]. Even young adults with HbSS are 
smaller than their age matched peers [6, 15], and have 
delayed pubertal development [16] reported a delay in 
menarcheal achievement in HbSS patients which was 
attributed to Hypothalamo-pituitary axis dysfunction. 
Heightened pro-inflammatory Cytokine production was 
reported in individuals with SCA during the steady state 
and in Vaso-Occlusive crisis [17, 18]. Several workers 
therefore reported chronic inflammation in patients 
with Sickle Cell disease [19, 20]. 
 In Nigerian HbSS children, factors responsible 
for their poor growth and several metabolic disorders 
had not been well researched. There were contradictory 
and varied results of endocrine dysfunctions in Hb-
SS patients. The study therefore bridged this gap in 
knowledge by assessing the physical characteristics 
(weight, height and Body Mass Index), plasma levels 
of Growth Hormone (GH), prolactin, cortisol, Total 
Thyroxin (TT4), Total Tri-iodotyronine (TT3), Thyroid 




 Twenty eight (28) HbSS children with vaso-
occlusive crisis attending Children Emergency Clinic 
at Ladoke Akintola University of Technology Teaching 
Hospital were recruited for this study. Another 30 
apparently healthy sex and age matched children with 
HbAA served as controls. Height and weight were 
measured using standard methods; and body mass 
index (BMI) of all participants calculated before being 
included in the study. 
 The participants aged  between (4 - 10 years) 
were recruited based on the report of [15] that lower 
height, weight and body mass index are demonstrated 
by HbSS children at age 4years. Hb-electrophoresis 
of each participant was carried out and those with 
HbSS and HbAA were selected for this study. Ethical 
clearance was obtained from the ethical committee, 
Ministry of Health, Osun state Government secretariat 
CONCLUSION 
 The lower levels of height, weight and BMI despite increased plasma level of GH could 
suggest peripheral tissue resistance and/or GH-receptor deficiency in HbSS children. Elevated 
cortisol levels and the positive correlation between cortisol and GH could suggest a link between 
metabolic stress and GH secretion in HbSS Children. 
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Abeere, Osogbo, Osun state, Nigeria. Verbal and written 
consents were obtained from parents of the children that 
participated in the study. 5mls of fasting blood sample 
was collected between 7.00 a.m and 9.00 a.m from every 
participant through venipuncture into lithium heparin 
bottles. The sample was centrifuged and the plasma 








  GH 
  Insulin and 
  Cortisol
 Plasma concentrations of TT3, TT4, TSH and 
prolactin were determined using commercially prepared 
enzyme linked immunosorbent assay (ELISA) reagents 
by Dialab, Gesellschaft, Vienna (cat. numbers Z01208, 
Z01232, Z01237 and Z05303 respectively). 
 GH, insulin and cortisol were determined using 
commercially prepared ELISA kits by CALBIOTECH, 
10461 Austin Drive, Suite G, Spring Valley, CA 
U.S.A (cat. numbers HG048H, IS130D and C0103S) 
respectively.
Statistical Analysis
 All statistical analyses were performed using 
Statistical Package for Social Sciences (SPSS) for 
windows, version 21. The data was expressed as Mean 
± SD. Student (t) test was used for the comparison of 
HbSS patients and controls. Pearsonian correlation 
coefficient (r) was calculated. The changes were 
considered significant, when p-values were less than 
0.05.
Results
      Physical characteristics of the participants are 
demonstrated in Table 1. The weight, height and BMI 
were significantly (p<0.05) lower in HbSS children 
compared with controls. As shown in Table 2, 
plasma levels of GH, cortisol, TT3 and TT4 increased 
significantly (p<0.05) in HbSS children compared with 
controls. There were no significant (p>0.05) differences 
in the plasma levels of prolactin, insulin and TSH in the 
HbSS children compared with the controls. 
 There was a significant (r - 0.46, p - 0.04) 
correlation between cortisol and Growth Hormone in 
the HbSS children (Table 3).  A negative correlation 
(r - -0.45, p - 0.045) existed between TT4 and weight of 
HbSS patients (Table 4).
Table 1:   Physical Characteristics of HbSS-Children and Controls.
Controls (N=30) HbSS (N=28) t-values p-value
Age (years) 7.45+1.79 6.20+2.28 3.707 0.062
Weight (Kg) 23.9+5.09 11.65+4.20 69.01 <0.001*
Height (M) 1.28+0.15 1.06+0.10 29.50 <0.001*
BMI (Kg/M2) 16.73+1.85 10.51+3.72 44.97 <0.001*
KEY     N   -   Sample size
 *   -  Significantly different from controls.
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Table 3: Correlation of Cortisol with GH, Prolactin, Insulin,  TT3, TT4 and TSH in  HbSS Children (N= 28)
Group r-value p-value
Cortisol / GH 0.46 0.04*
Cortisol / Prolactin -0.34 0.14
Cortisol / insulin -0.19 0.43
Cortisol / TT3 -0.03 0.89
Cortisol / TT4 0.05 0.84
Cortisol / TSH 0.11 0.63
Where  N   =    Sample size
  *    =    Significant correlation
KEY N   - Sample size
 *    - Significantly different from controls.
Controls (N=30) HbSS (N=28) p-value
Growth Hormone (ng/ml) 0.92 ± 0.56 1.73± 1.68 0.049*
Cortisol (ng/ml) 99.35 ± 38.81 176.85± 105.87 0.004*
TT3 (ng/ml) 4.25±3.69 7.11+2.73 0.008*
TT4 (ng/ml) 36.97±30.44 59.95±22.41 0.010*
TSH(mIU/l) 0.25±0.14 0.23± 0.18 0.690
Insulin (mIU/ml 8.02±2.90 7.81±1.60 0.721
Prolactin (ng/ml) 4.17±2.05 4.04±1.83 2.080
Table 2:  Plasma Levels of TT3, TT4, TSH, Growth Hormone, Prolactin, Insulin and Cortisol in HbSS Children and Controls
African Journal of Health Sciences  Volume 33, Issue No.1, January - February, 202018
Table 4:   Correlation of Weight with Growth Hormone, Cortisol, Prolactin, Insulin,  TT3, TT4 and  
    TSH in  HbSS-Children (N= 28)
Group r-value p-value
Weight/Cortisol -0.21 0.38
Weight /GH -0.28 0.23
Weight /Prolactin -0.34 0.14
Weight /insulin -0.19 0.43
Weight /TT3 -0.12 0.61
Weight /TT4 -0.45 0.045*
Weight /TSH -0.03 0.90
Where  N   -    Sample size
  *    -    Significant correlation
Discussion
 Previous studies show that HbF is highest (98%) 
at birth decreasing at 5% per week till 6th month when it 
wanes off. 
 Therefore, HbSS children are apparently normal 
at birth, but by 2–5 years of age when the hemoglobins 
are predominantly SS, significant physiological 
deficits are apparent and several characteristics such as 
suboptimal growth, Haemolytic anemia and immune 
dysfunction manifest [6, 7]. 
 The suboptimal growth was confirmed in 
this study with significantly reduced height, weight 
and BMI observed in our HbSS children. Continuous 
tissue breakdown, increased inflammatory Cytokines, 
malnutrition due to anorexia, hypoxia and growth 
hormone metabolic disorders could contribute to the 
loss of weight in these HbSS children. Our finding agree 
with [15] who reported that, lower height, weight and 
body mass index were demonstrated by HbSS children. 
The present findings also corroborate that of [21] who 
reported growth failure and maturational delay remain 
significant chronic problems in HbSS children.
 Under physiological condition, cortisol 
mobilized Triglycerides to Visceral Fat Cells to aid 
Adipocytes development into mature fat cells. It also 
played a significant role in glucose metabolism, protein 
metabolism, inhibiting the production of inflammatory 
Cytokines that improved the hemodynamic status of the 
respondent [22 - 23].
  Previous studies show that, excess cortisol 
suppresses the immune system, decreased amino acid 
uptake by muscle, inhibited collagen formation and 
decreased bone formation [24 - 26]. 
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 The elevated cortisol level observed in the 
study could be due to a response to stress, which 
might have antagonized the physiological effects of 
Growth Hormone in the HbSS children. This findings 
did not agree with independent reports of significant 
lower levels of cortisol in both male and female HbSS 
patients [27 - 28]. 
 The contradictory reports by previous 
researchers might be due to inconsistency in the 
clinical conditions and age status of the HbSS patients 
used for their studies. For example, induced stress 
through insulin Hypoglycaemia test in HbSS patients 
during crisis and non-crisis periods, reported lower 
level of plasma cortisol during painful crises [29]
 However, this study seems to ratify the report 
that, cortisol levels increased significantly during 
painful crisis in the HbSS patients. It demonstrated 
increased levels of Growth Hormone in HbSS children 
despite the suboptimal growth observed in them. 
Elevated Growth Hormone Level could be due to 
peripheral tissue resistance or GH-receptor deficiency 
in those children. Assumption of impairments in the 
regulatory feedback mechanisms of the Hypothalamic-
Pituitary axis leading to continuous secretion of 
Growth Hormone in the HbSS children could not be 
under-estimated [30]. 
 The correlation between Cortisol and Growth 
Hormone might confirm the effect of metabolic stress 
on Growth Hormone secretion in these children. The 
report does not support several previous researches 
which reported lower levels of Growth Hormone in 
HbSS patients while other researches reported that, 
growth delay was associated with anemia and deficiency 
of certain nutritional factors rather than endocrine 
abnormalities [31,32]. 
 The report to partially corroborate with an 
earlier one which reported a slightly higher level of 
GH in HbSS patients with age range of  4 - 50 years. 
The levels of Growth Hormone reported in many of 
those earlier studies therefore contradict our report, 
possibly because those facilitators recruited both 
adults and young HbSS patients and failed to consider 
only growing children with optimal Growth Hormone 
secretion in their studies [33]. 
 Several researches have reported significant 
metabolic changes in human and animal models with 
Thyroid hormone disorders. The T3 is the key metabolic 
regulator coordinating short-term and long-term energy 
needs [34]. Elevated levels of plasma TT3 and TT4 in 
HbSS children recruited for this study might be due to 
higher basal metabolic requirement, tissue resistance 
to Thyroid hormones and or selective resistance in the 
pituitary gland. 
Since ;  T3 is 25 % bound to albumin and 75 % bound
    to thyroid binding globulin,
while ;   T4 is 20 % bound to Thyroid binding pre-   
   albumin, 75 % bound to thyroid binding  
   globulin and 5% to albumin, 
the hyperglobulinaemia due to immune response to 
infections might have contributed to the higher levels of 
total T3 and total T4 in our HbSS children.
 A negative correlation reported between TT4 
and weight of HbSS patients could confirm the effect 
of hyperthyroidism on weight loss. Our finding seems 
to agree with [33] who reported that, free T3 and T4 
were slightly higher in the HbSS patients compared to 
the controls. In other studies, the levels of total T3 and 
T4 were reported to be within the normal range in HbSS 
patients. 
 However, the significantly higher levels in many 
studies have shown that the basal metabolic rates were 
significantly increased in HbSS patients [31, 32, 35, 36]. 
This elevated thyroid hormone levels could contribute 
to the already established increased metabolic rate, and 
the loss of weight observed in the HbSS children. 
 Prolactin is a stress induced hormone that 
plays physiological roles only during pregnancy and in 
lactating mothers. Apart from Pituitary Adenoma and 
stress that enhance prolactin secretion in adults, the 
plasma level increases in newborn babies due to high 
level of maternal estradiol transferred to the baby in-
utero and declines after birth. In this study, prolactin 
level did not show significant change in HbSS children. 
The study confirms the findings of   [37] who reported 
insignificant change in the level of prolactin in HbSS 
patients. 
 However, the only report of hyperprolactinemia 
in HbSS patients was due to pituitary adenoma [38]. 
Insulin played critical roles in the metabolisms of 
Growth Hormone, glucose, proteins and lipids [39]. 
 Several studies failed to show the co-existence 
of insulin metabolic dysfunction and Sickle Cell disease. 
Lack of reported cases of Type 1 diabetes mellitus in 
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patients with HbSS suggested that, HbSS might be 
protective against the development of Type 1 diabetes 
mellitus. Also in the study, there was no significant 
change in the level of insulin in our HbSS children. This 
study contradicts [40] who reported that, normoglycemic 
patients with Sickle Cell disease demonstrated impaired 
β-cell	function	with	reduced	insulin	secretion.	
 Meanwhile, our finding seems to support the 
report of [41] who reported that; 
a. There were no cases of Sickle Cell disease in the 
diabetic population.
b. All Sickle Cell disease patients demonstrated 
normal glucose tolerance, with insulin and 
glucagon responses.
Conclusion
     In conclusion, increased levels of cortisol, Thyroid 
Hormones and Growth Hormones are possible features 
of children with Hemoglobin-SS (HbSS). Peripheral 
tissue resistance and other unknown factors might 
account for increased plasma level of growth hormone 
in the HbSS children.
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